Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So

HC Wainwright has removed Angion Biomedica Corp's ANGN former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation assessment. The analyst has reduced the price target from $50 to $32, with a Buy rating.
In the Q4 earnings release, the Company decided to discontinue the development of ANG-3777 after disappointing data.
The analyst believes that the Company is better positioned than the market appears to think, particularly in light of the Company's currently negative enterprise value of $(32.56) million, as per Benzinga Pro.
It possesses an extensive pipeline of assets beyond ANG-3777, which the market does not appear to be taking into consideration, analysts note.
Related: Angion's ANG-3777 Faces Third Failure In 2021, This Time Flunks Acute Kidney Injury Trial.
HC Wainwright expects topline data from the Phase 2 trial of ANG-3070 in patients with primary proteinuric kidney diseases during 2H of 2022.
It expects IND submission for ANG-3070 in patients with idiopathic pulmonary fibrosis by the end of 2022.
The analyst expects FY22 EPS of $(1.64) vs. the previous $2.13 reflecting lower projected operational expenses on discontinuation of ANG-3777.
Last December, CSL agreed to acquire Angion's partner Vifor Pharma in a deal worth $11.7 billion.
"We now anticipate that Vifor, as a CSL subsidiary, shall likely formally discontinue its partnership with Angion on ANG-3777 once the close-out of data analyses from the clinical studies of the compound has been completed" writes HC Wainwright.
Price Action: ANGN shares are up 1.16% at $1.75 during the market session on the last check Monday.

Market News and Data brought to you by Benzinga APIs

Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga